XML 17 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated statements of profit or loss and other comprehensive income - AUD ($)
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Profit or loss [abstract]      
Revenue from continuing operations $ 15,183,000    
Other income 2,000 $ 995,000 $ 1,465,000
Finance income - bank interest 42,000 66,000 100,000
Expenses      
Research and development expense (14,541,000) (9,494,000) (6,475,000)
General and administrative expense (7,022,000) (3,690,000) (3,785,000)
Loss on disposal of fixed assets     (1,000)
Fair value losses on financial assets at fair value through profit or loss 0 (168,000) (1,809,000)
Loss on revaluation of contingent consideration (2,570,000) (474,000) (63,000)
Loss before income tax expense from continuing operations (8,906,000) (12,765,000) (10,568,000)
Income tax benefit 484,000 298,000 298,000
Loss after income tax expense for the year (8,421,960) (12,467,466) (10,270,000)
Items that may be reclassified subsequently to profit or loss      
Net exchange difference on translation of financial statements of foreign controlled entities, net of tax 2,000 (4,000) (89,000)
Other comprehensive income for the year, net of tax 2,000 (4,000) (89,000)
Total comprehensive income for the year (8,420,000) (12,471,000) (10,359,000)
Loss for the year is attributable to:      
Owners of Kazia Therapeutics Limited (8,422,000) (12,467,000) (10,270,000)
Loss after income tax expense for the year (8,421,960) (12,467,466) (10,270,000)
Total comprehensive income for the year is attributable to:      
Owners of Kazia Therapeutics Limited (8,420,000) (12,471,000) (10,359,000)
Total comprehensive income for the year $ (8,420,000) $ (12,471,000) $ (10,359,000)
Earnings per share for loss from continuing operations attributable to the owners of Kazia Therapeutics Limited      
Basic earnings per share $ (7.16) $ (17.07) $ (17.86)
Diluted earnings per share (7.16) (17.07) (17.86)
Earnings per share for loss attributable to the owners of Kazia Therapeutics Limited      
Basic earnings per share (7.16) (17.07) (17.86)
Diluted earnings per share $ (7.16) $ (17.07) $ (17.86)